Tag : Interstitial Lung Disease

Pediatrics

Researchers Use Gene Editing with CRISPR to Treat Lethal Lung Diseases before Birth

Newsemia
Researchers used CRISPR gene editing to thwart a lethal lung disease in an animal model in which a harmful mutation causes death within hours after...
Latest News

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Newsemia
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with...
Latest News

Researchers identify common genetic connection in lung conditions

Newsemia
An international research team led by members of the University of Colorado School of Medicine faculty has identified a genetic connection between rheumatoid arthritis-associated interstitial...
Gastroenterology

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Newsemia
Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line)...
Gastroenterology

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Newsemia
Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint. Source link...
Gastroenterology

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Newsemia
Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy